Retatrutide (LY3437943) is an investigational peptide drug being developed for obesity, type 2 diabetes, and metabolic diseases.
- It belongs to a new class called “triple agonists”
- Administered as a once-weekly or Microdose injection
- Not yet FDA-approved (currently in Phase 3 trials)
👉 What makes it unique:
It simultaneously activates three key metabolic hormone receptors:
- GLP-1 (glucagon-like peptide-1)
- GIP (glucose-dependent insulinotropic polypeptide)
- Glucagon (GCG)
This “triple-action” design is why it’s often called a next-generation weight loss and metabolic therapy.
Features
- Triple agonist peptide studied for metabolic regulation
- Targets GLP-1, GIP, and glucagon receptor pathways
- Investigated for appetite suppression and fat loss applications
- Potential to support insulin sensitivity and glucose homeostasis
- Used in research exploring obesity, diabetes, and energy balance
- May influence thermogenesis, body composition, and satiety signaling
Specs
- Volume: 10 OR 20 MG
- Purity: Research Grade
- Composition: Retatrutide (Triple Agonist Peptide)
Reviews
There are no reviews yet.